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Abstract
Background: We investigate the effect of a high dose 
of vitamin D3 on circulating concentrations of 25(OH)
D3 and its metabolites 24,25(OH)2D3, 3-epi-25(OH)
D3, and 1,25(OH)2D3 in healthy individuals with self-
perceived fatigue and vitamin D insufficiency [25(OH)
D3 <50 nmol/L].
Methods: One hundred and seven study participants (age 
20–50 years) were randomized to receive a single 100,000 
IU dose of vitamin D3 (n = 52) or placebo (n = 55). Vitamin 
D metabolite concentrations in serum were measured 
before, and 4 weeks after, supplementation.
Results: Overall, 52% of participants receiving vitamin 
D3 attained a serum 25(OH)D3 level >75 nmol/L. Among 
individuals who received vitamin D3, there were sig-
nificant increases in serum concentrations of 25(OH)D3 
and its metabolites 24,25(OH)2D3, 3-epi-25(OH)D3, and 
1,25(OH)2D3 at 4 weeks; however, inter-individual variabil-
ity in these changes was substantial. Positive correlations 
between serum 25(OH)D3 and 24,25(OH)2D3 and 3-epi-
25(OH)D3, and a significant negative correlation between 
serum 1,25(OH)2D3 and 3-epi-25(OH)D3, were found 
4 weeks after supplementation. The 24,25(OH)2D3/25(OH)
D3 and 24,25(OH)2D3/1,25(OH)2D3 ratios were significantly 
increased, compared with baseline, in participants receiv-
ing vitamin D3. Baseline 25(OH)D3 concentration was 
the only factor predictive of the change in 25(OH)D3 after 
supplementation.
Conclusions: Administration of a single high dose of vita-
min D3 leads to a significant increase in concentrations of 
25(OH)D3, 24,25(OH)2D3, 3-epi-25(OH)D3 and 1,25(OH)2D3; 
induction of the catabolic pathway predominates over the 
production of 1,25(OH)2D3. Due to the high inter-individ-
ual variation in the 25(OH)D3 response to supplementa-
tion, any given dose of vitamin D is unlikely to achieve 
optimal vitamin D status in all treated individuals
Keywords: 1,25(OH)2D3; 24,25(OH)2D3; 25(OH)D3; 3-epi-
25(OH)D3; supplementation; vitamin D.
Introduction
Vitamin D plays a key role in the regulation of calcium and 
phosphate homeostasis, and deficiency of this vitamin 
is associated with secondary hyperparathyroidism, an 
increase in bone turnover and bone loss [1]. Vitamin D syn-
thesized in the skin [vitamin D3 (cholecalciferol)] or orally 
ingested [either vitamin D3 or vitamin D2 (ergocalciferol)] 
is metabolized in the liver by the enzyme 25-hydroxy-
lase (CYP2R1) to form 25-hydroxy vitamin D3 [25(OH)D3], 
which is then further metabolized primarily in the kidney 
by 1α-hydroxylase (CYP27B1) to form the active vitamin D 
metabolite, 1,25-dihydroxy vitamin D3 [1,25(OH)2D3]. Both 
25(OH)D3 and 1,25(OH)2D3 undergo further metabolism, 
predominantly by renal 24-hydroxylase (CYP24A1), to 
generate 24,25-dihydroxy vitamin D3 [24,25(OH)2 D3] and 
1,24,25-trihydroxyvitamin D3 [1α,24,25(OH)3D3], respec-
tively [2–4]. Mutations in the CYP24A1 gene are associ-
ated with partial or total loss of 24-hydroxylase activity, 
which in turn leads to hypercalcaemic conditions [5–7]. 
The production of 24,25(OH)2D3  has been shown to be 
25(OH)D3-dependent, and is moderately affected by 
*Corresponding author: Dr. Lanja Saleh, Institute for Clinical 
Chemistry, University Hospital of Zurich and University of Zurich, 
Raemistr. 100, Zurich, Switzerland, Phone: +41 44 255 2293,  
Fax: +41 44 255 4590, E-mail: lanja.saleh@usz.ch
Jonathan Tang and William D Fraser: Bioanalytical Facility, Bob 
Champion Research and Education Building, James Watson Road, 
University of East Anglia, Norwich Research Park, Norwich, UK
Joanna Gawinecka and Arnold von Eckardstein: Institute for Clinical 
Chemistry, University Hospital of Zurich and University of Zurich, 
Zurich, Switzerland
Lukas Boesch and Albina Nowak: Division of Internal Medicine, 
University Hospital of Zurich and University of Zurich, Zurich, 
Switzerland
Bereitgestellt von | UZH Hauptbibliothek / Zentralbibliothek Zürich
Angemeldet
Heruntergeladen am | 23.06.17 12:38
2      Saleh et al.: Impact of a single oral dose of 100,000 IU vitamin D3 on vitamin D metabolite profiles
vitamin D supplementation [5, 6]; the physiological role 
of this metabolite remains to be established, although it is 
known to be involved in embryogenesis, cartilage devel-
opment and fracture repair [8–10].
Measurement of total 25(OH)D [comprising both 
25(OH)D3 and 25(OH)D2] in serum is widely accepted as a 
marker of vitamin D status; however, the optimum thresh-
old concentration of 25(OH)D continues to be debated. 
The Institute of Medicine (IOM) recommends a threshold 
of 50 nmol/L for bone health [11], whereas the Endocrine 
Society recommend a threshold of 75 nmol/L for optimal 
reductions in fall or fracture risk [1].
The 25(OH)D3 response to vitamin D supplementation 
varies markedly between individuals, and a significant 
proportion of patients may have persistent suboptimal 
levels despite supplementation [12–17]. Furthermore, the 
relationship between circulating 25(OH)D3 concentra-
tions and clinical outcomes such as osteoporosis and 
fracture risk may differ between racial groups, raising the 
question of whether 25(OH)D3 provides a reliable estimate 
of vitamin D status in all populations [18, 19]. For these 
reasons, increasing attention is being paid to the measure-
ment of 24,25(OH)2D3 (the major circulating catabolite of 
vitamin D), and the ratio of 24,25(OH)2D3 to 25(OH)D3, as 
potential markers of vitamin D catabolism and predictors 
of the serum 25(OH)D response to vitamin D supplementa-
tion [5, 6, 12, 18, 20].
Measurement of vitamin D metabolites as biomark-
ers of vitamin D status has been further complicated in 
recent years by the identification of C3 epimeric forms of 
25(OH)D3 and 1,25(OH)2D3 [21]. These epimers were origi-
nally identified in infants and neonates, in whom they 
account for approximately 21% of total 25(OH)D3 concen-
trations [21], but were subsequently shown to be present 
in lower concentrations in adults, in whom they account 
for approximately 6% of total 25(OH)D3 [21–23]. The 3-epi-
25(OH)D3  metabolite is produced endogenously, and 
circulating concentrations increase following vitamin D 
supplementation [22]; however, the physiological signifi-
cance of these epimers remains to be established [20, 21].
In view of the continuing uncertainty surrounding 
the clinical utility of different vitamin D metabolites as 
markers of vitamin D status, and to better understand the 
vitamin D metabolism pathway in response to supplemen-
tation, the present study was performed to investigate the 
effect of a single high dose (100,000 IU) of vitamin D3 
on profiles of circulating 25(OH)D3 and its metabolites 
24,25(OH)2D3, 3-epi25(OH) D3, and 1,25(OH)2D3 in healthy 
individuals with self-perceived fatigue and vitamin D 
insufficiency [25(OH)D3 <50  nmol/L], and to assess the 
inter-individual variability in the response to vitamin D 
supplementation. A further objective was to investigate 
the hypothesis that the baseline 24,25(OH)2D3/25(OH)D3 
ratio is a predictor of the response to supplementation.
Materials and methods
Clinical samples
Frozen serum samples (n = 214) were obtained from a prospective 
randomized, double-blind, placebo-controlled clinical trial con-
ducted at the University Hospital of Zurich, Switzerland (latitude 
47°22′ N) (ClinicalTrials.gov Registry number NCT02022475). The trial 
was conducted in accordance with the declaration of Helsinki and 
Good Clinical Practice guidelines; the study protocol and its amend-
ment were approved by the Zurich Cantonal Ethical Committee and 
Swissmedic, and informed consent was obtained from all partici-
pants prior to enrolment. The primary aim of the trial was to deter-
mine the effects of a single high dose of vitamin D3, compared with 
placebo, on serum 25(OH)D3 concentrations and clinical outcomes 
such as fatigue at 4 weeks after treatment. Full details of this trial has 
been described elsewhere [23].
The trial involved 107 participants [age 20–50 years, body mass 
index (BMI) 18–25 kg/m2] who had serum 25(OH)D3 concentrations 
below 50 nmol/L. The 50 nmol/L threshold for vitamin D insufficiency 
was used in accordance with the recommendation of the Institute of 
Medicine (IOM) [11]. Participants were randomized to receive either 
a single 100,000 IU dose of vitamin D3 (n = 52) or placebo (n = 55).
Blood samples were obtained at a screening visit immediately 
before treatment and at a second visit 4 weeks after supplementation. 
Serum was separated by centrifugation at 2000 g for 10 min, and ali-
quots were stored at −80 °C prior to analysis. Serum concentrations 
of 25(OH)D3, 3-epi 25(OH)D3, 24,25(OH)2D3 and 25-hydroxy vitamin 
D2 [25(OH)D2] were measured by a validated NIST traceable LC-MS/
MS assay using a Micromass Quattro Ultima Pt mass spectrometer 
(Waters Corp., Milford, MA, USA) at Bioanalytical Facility, University 
of East Anglia, Norwich, UK; details of the assay are provided in the 
online supplementary material. For all analytes, the assay showed 
good linearity (r2 ≥0.98) and low intra-assay and inter-assay variabil-
ity (see Supplementary Table S1).
Measurements of total 1,25(OH)2D3 were performed using a com-
mercial immunoextraction enzyme immunoassay kit (IDS, Bolden, 
UK). The inter- and intra-assay imprecision, as expressed by the 
coefficient of variation (CV), was less than 12.5%. Serum concentra-
tions of calcium, phosphate, parathyroid hormone (PTH), C-reactive 
protein (CRP), and creatinine were measured using a Cobas 8000 
analyzer (Roche Diagnostics, Mannheim, Germany) at the Institute 
of Clinical Chemistry, University Hospital of Zurich. All analyses were 
carried out according to the manufacturer’s instructions. For all ana-
lytes, intra-assay and inter-assay variability, as expressed by the coef-
ficient of variation (CV), were ≤1.7% and 3.1%, respectively.
Statistical analyses
Demographic data and serum concentrations of vitamin D metabo-
lites at baseline and follow-up were summarized using descriptive 
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statistics (means, SDs, medians and interquartile ranges). Differ-
ences between baseline and post-supplementation values were ana-
lysed by means of paired t tests for vitamin D metabolites, unpaired 
t-tests for normally distributed demographic variables, Mann-Whit-
ney rank tests for non-normally distributed variables, and χ2 tests for 
categorical variables. All comparisons were two-sided. Associations 
between vitamin D3  metabolites, and other clinical variables (age, 
BMI, serum calcium, serum phosphate and serum PTH), at baseline 
and at 4 weeks after supplementation were investigated using Spear-
man rank correlation analysis.
Simple and multiple regression analyses were used to build 
prediction models for the 25(OH)D3 response to vitamin D3 supple-
mentation. Four different models were used: model 1 included only 
baseline 25(OH)D3 concentrations as covariate; model 2 included 
baseline 25(OH)D3, 24,25(OH)2D3 and 3-epi-25(OH)D3 concentrations 
as covariates; model 3 included the same covariates as model 2 in 
addition to age, gender and body mass index (BMI), while model 4 
included baseline 1,25(OH)2D3 concentrations in addition to the same 
covariates as model 2. All analyses were performed using IBM SPSS 
Statistics 22  software (SPSS Inc., Chicago, IL, USA), and p-values 
below 0.05 were considered significant.
Results
Baseline demographic and clinical characteristics of study 
participants are summarized in Table  1. No statistically 
significant differences between the vitamin D supple-
mented and placebo groups were observed. At baseline, 
3-epi-25(OH)D3 was present in 88% of study participants, 
at a mean concentration equivalent to 3.9% of serum 
25(OH)D3 concentrations (Table 1).
Changes in vitamin D metabolites following 
vitamin D supplementation
Serum concentrations of vitamin D metabolites at base-
line are summarized in Table 1, and changes in these con-
centrations 4 weeks after a single oral dose of 100,000 IU 
vitamin D3 are presented in Figure 1. At 4 weeks, partici-
pants receiving vitamin D3 showed significant absolute 
increases in serum 25(OH)D3, 24,25(OH)2D3, 3-epi-25(OH)
D3 and 1,25(OH)2D3 concentrations (all p < 0.001 vs. base-
line), whereas no such changes were seen in placebo-
treated participants.
Interestingly, the ratios of 24,25(OH)2D3 to 25(OH)
D3 and 24,25(OH)2D3 to 1,25(OH)3D3  were significantly 
increased, compared with baseline, in study partici-
pants receiving vitamin D3  supplementation (Figure  1). 
The mean 24,25(OH)D3/25(OH)D3 ratio at baseline was 
0.076 ± 0.02, and this had increased to 0.086 ± 0.02 
(p = 0.006) at 4  weeks after supplementation. Similarly, 
the ratio of 24,25(OH)2D3 to 1,25(OH)2D3 increased 2.4-fold 
after vitamin D3  supplementation, from 0.023 ± 0.01 at 
baseline to 0.056 ± 0.025 (p < 0.0001) at 4 weeks. In partici-
pants receiving placebo, both ratios remained unchanged 
following supplementation (p = 0.36 and p = 0.92, respec-
tively, vs. baseline), as shown in Figure 1E and F.
At 4 weeks after dosing, all participants in the vitamin 
D3 group had attained a serum 25(OH)D3 concentration 
≥50  nmol/L, except for one patient in whom the 25(OH)
D3 concentration increased from a baseline value of 
17.5  nmol/L to 35.6  nmol/L. Overall, 52% of participants 
Table 1: Baseline demographic and clinical characteristics.
Therapy (n = 52) Placebo (n = 55) p-Value
Age, years 29 (6) 28 (6) 0.30
Gender, females/males 27/25 (52%/48%) 26/29 (47%/53%) 0.15a
BMI, kg/m2 22 (2) 22 (2) 0.54
Arterial blood pressure, mmHg
 Systolic 123 (11) 126 (11) 0.16
 Diastolic 78 (9) 77 (8) 0.44
Parathyroid hormone, ng/L 44 (16) 46 (18) 0.59
Calcium, mmol/Lb 2.23 (0.07) 2.22 (0.07) 0.97
Phosphate, mmol/L 0.99 (0.18) 1.00 (0.15) 0.69
Creatinine, μmol/L 71 (14) 75 (13) 0.13
C-reactive protein, mg/Lc 0.5 (0.0–1.2) 0.6 (0.3–1.8) 0.27
24,25(OH)2D3, nmol/L 2.2 (0.9) 2.5 (1.0) 0.08
25(OH)D3, nmol/L 28 (9) 32 (11) 0.06
1,25(OH)2D3, pmol/L 100 (29) 94 (25) 0.23
3-epi-25(OH)D3, nmol/L 1.0 (0.9) 1.3 (0.93) 0.08
25(OH)D2, nmol/Lc 1.8 (1.1–2.2) 2 (1.4–2.6) 0.06
Data are shown as mean (SD), and groups were compared using unpaired two-sided t tests, unless indicated otherwise. aχ2-test; badjusted 
for serum albumin concentrations; cmedian (interquartile range).
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receiving vitamin D3  supplementation attained a serum 
25(OH)D3 concentration of >75 nmol/L, while 46% attained 
a serum 25(OH)D3 concentration between 50 and 75 nmol/L. 
No significant differences were observed in vitamin D 
metabolite concentration changes from baseline in study 
subjects who attained 25(OH)D3 concentration between 50 
and 75 nmol/L, as compared to those who attained a serum 
25(OH)D3 concentration >75 nmol/L (Table 2).
Substantial inter-individual variability in changes 
in serum 25(OH)D3, 3-epi-25(OH)D3, 24,25(OH)2D3 and 
1,25(OH)2D3  was observed following administration of 
100,000 IU vitamin D3. This variability was not dependent 
Figure 1: Absolute changes in vitamin D metabolites from baseline (dark shading) to 4 weeks after (light shading) a single 100,000 IU oral 
dose of vitamin D3.
(A) 25(OH)D3; (B) 24,25(OH)D3; (C) 1,25(OH)2 D3; (D) 3-epi-25(OH)D3; (E) 24,25(OH)2D3/(25(OH)D3; (F) 24,25(OH)2D3/1.25(OH)2D3.
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on baseline serum levels of the respective analytes, as 
shown in Figure 2.
Overall, 25(OH)D3 accounted for approximately 89%–
90% of circulating vitamin D metabolites at baseline, 
24,25(OH)2D3 accounted for 7%, and 3-epi-25(OH)D3 for 
approximately 3%–4%. These proportions did not change 
after vitamin D3 supplementation (Figure 3).
Correlations between vitamin D3 metabolites before and 
after vitamin D3 supplementation
In the overall study population (n = 107), there were sig-
nificant correlations at baseline between serum con-
centrations of 25(OH)D3 and 1,25(OH)2D3, 24,25(OH)2D3 
or 3-epi-25(OH)D3 (ρ = 0.39, 0.86 and 0.36, respectively; 
Table 2: Mean ( ± SD) vitamin D metabolite concentration changes from baseline in supplemented subjects who attained serum 25(OH)D3 
concentrations between 50 and 75 nmol/L vs. those who attained a serum 25(OH)D3 concentration >75 nmol/L, 4 weeks after a single oral 
dose of 100,000 IU vitamin D3 administration.
Vitamin D metabolites 50–75 nmol/L (n = 24) >75 nmol/L (n = 27) p-Value
25(OH)D3, nmol/L 39.2 ± 10.3 59.6 ± 18.9  <0.001
24,25(OH)2D3, nmol/L 3.9 ± 1.2 4.9 ± 2.8 0.13
1,25(OH)2D3, pmol/L 20.9 (−29.4–78.0)a 32.3 (−45.8–83.5)a 0.20a
3-epi-25(OH)D3, nmol/L 1.7 ± 1.6 2.4 ± 1.9 0.17
24,25(OH)2D3/25(OH)D3 0.091 ± 0.016 0.081 ± 0.026 0.10
24,25(OH)2D3/1,25(OH)2D3 0.053 ± 0.017 0.060 ± 0.031 0.36
aMedian (5th–95th percentile), Mann-Whitney test.
Figure 2: Changes in serum 25(OH)D3 (nmol/L) (A, B), 1,25(OH)2D3 (pmol/L) (C, D), 24,25(OH)2D3 (nmol/L) (E, F), 3-epi-25(OH)D3 (nmol/L) 
(G, H) concentrations from baseline to 4 weeks after vitamin D supplementation in individual participants.
Open circles: baseline, black-filled circles: post-supplementation; asterisks indicate participants specifically referred to in the discussion.
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p < 0.001 for all) as shown in Figure  4. Serum concen-
trations of 24,25(OH)2D3 at baseline correlated signifi-
cantly with 3-epi-25(OH)D3 (ρ = 0.37, p < 0.001), but there 
were no other significant correlations between the other 
metabolites. There were also weak but significant corre-
lations at baseline between serum 25(OH)D3 and calcium 
concentrations (ρ = 0.24, p = 0.013), and between serum 
24,25(OH)2D3 and PTH concentrations (ρ = 0.20, p = 0.043).
Among participants who received vitamin D3  sup-
plementation (n = 52), there were significant positive 
correlations at 4 weeks between serum 25(OH)D3 concen-
trations and 24,25(OH)2D3 (ρ = 0.47, p < 0.001) and 3-epi-
25(OH)D3 (ρ = 0.35, p = 0.011), and a significant negative 
correlation between serum 1,25(OH)2D3 and 3-epi-25(OH)
D3 (ρ = −0.46, p < 0.001). The change in serum 25(OH)D3 
concentrations from baseline to 4  weeks after supple-
mentation was significantly correlated with the change 
in 24,25(OH)2D3 concentrations (ρ = 0.49, p < 0.0001), 
but not with changes in 1,25(OH)D2D3 concentrations 
(ρ = 0.05, p = 0.71).
Predictors of 25(OH)D3 response to vitamin 
D3 supplementation
Multiple regression analyses were performed to identify 
predictors of the 25(OH)D3 response to vitamin D3  sup-
plementation. The results of these analyses are summa-
rized in Table 3. The variance in the 25(OH)D3 level after 
supplementation explained by a simple regression model 
that included only 25(OH)D3 at baseline was 15% (R2 = 0.17, 
Figure 3: Relative proportions of vitamin D3 metabolites in serum at 
baseline (visit A) and 4 weeks after a 100,000 IU single oral dose of 
vitamin D3 or placebo (visit B).
F(1,50) = 10.2, p = 0.002) Adjustment for other vitamin 
D3 metabolites [1,25(OH)2D3, 24,25(OH)2D3 or 3-epi-25(OH)
D3], age, sex or BMI did not further improve the predic-
tion of 25(OH)D3 levels after supplementation. Similarly, 
other putative markers of vitamin D3  status, including 
the 24,25(OH)2D3/25(OH)D3 ratio alone or in combination 
with age, sex, and BMI were not predictive of 25(OH)D3 
concentrations after vitamin D3  supplementation. None 
of the regression models could predict the variance in the 
25(OH)D3 change after supplementation (Table 3).
Changes in other circulating biomarkers 
of calcium homeostasis
Participants receiving vitamin D supplementation showed 
a significant decrease in PTH concentrations at 4 weeks, 
whereas PTH concentrations were increased in placebo-
treated participants (mean change −2.6 ± 13 vs. 3.9 ± 18 
ng/L, respectively; p = 0.03). Calcium and phosphate con-
centrations remained unchanged in both groups.
Discussion
This study has shown that serum concentrations of 
25(OH)D3, 24,25(OH)2D3, 3-epi-25(OH)D3 and 1,25(OH)2D3 
all increase significantly 4 weeks after a single high oral 
dose of 100,000 IU vitamin D3, whereas no such changes 
are seen in placebo-treated participants. The increase in 
25(OH)D3 concentrations after supplementation was sig-
nificantly associated with the increase in 24,25(OH)2D3 
concentrations after supplementation.
Taking the 24,25(OH)2D values and the ratio of 
24,25(OH)2D/25(OH)D3 and 24,25(OH)2D3/1,25(OH)2D3 as 
markers of vitamin D catabolism, we found significant 
increases in these variables following supplementation 
with a high dose of vitamin D3, which indicates induction 
of the vitamin D catabolic pathway. This suggests that, 
when adequate amounts of biologically active vitamin D 
are available, the production of the vitamin D catabolite 
24,25(OH)D is favoured over the active metabolite 1,25(OH)
D3, due to increased activity of 24-hydroxylase (CYP24A1), 
thereby avoiding excessive production of 1,25(OH)D3 and 
associated toxicity. Interestingly, a previous study from 
our group, which analysed vitamin D metabolite pro-
files in three supplementation studies, showed that the 
production of 24,25(OH)2D3 is favoured over 1,25(OH)2D3 
following administration of high doses of vitamin D3, 
compared with lower doses [20].
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The majority of participants receiving vitamin D3 
attained serum 25(OH)D3 concentrations above 50 nmol/L, 
a widely accepted threshold for vitamin D insufficiency 
[11], but only 52% of subjects attained serum 25(OH)D3 con-
centrations above 75 nmol/L. This indicates that the use of 
a single high dose of vitamin D is not sufficient to ensure 
that adequate vitamin D levels are attained in all study 
participants. This would be consistent with the finding by 
Binkley et al. [14] that suboptimal 25(OH)D3 levels persisted 
in approximately 20% of individuals despite dosing with 
Figure 4: Correlations between baseline concentrations of vitamin D metabolites.
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vitamin D3, 50,000 IU monthly, for 1 year. Furthermore, 
our results demonstrate large inter-individual variations in 
the increase in 25(OH)D3 and 24,25(OH)2D concentrations 
following administration of 100,000 IU vitamin D3. In 
addition, we provide the first evidence that the increase in 
the 3-epimer 25(OH)D metabolite following vitamin D sup-
plementation also shows large inter-individual variation 
in adults, probably due to modifying factors, as has previ-
ously been described for 25(OH)D3 and 24,25(OH)2D3 [5, 12, 
14, 16]. This inter-individual variability in both 24,25(OH)
D3 and 3-epi-25(OH)D3 contributes to the observed inter-
individual variation in the response to vitamin D3 supple-
mentation. For example, looking at Figure 2, it can be seen 
that participants 45 and 47 in the vitamin D supplementa-
tion group had similar baseline concentrations of 25(OH)
D3, but the increases in 24,25(OH)2D3 and 3-epi25(OH)D3 
following supplementation differed markedly between the 
two participants. These large individual variations in the 
response to supplementation should be taken into account 
when giving recommendations for vitamin D supplemen-
tation. Clearly, a single fixed dose of vitamin D will not 
suffice to ensure adequate 25(OH)D levels in all patients 
unless the dose is very large, thereby increasing the risk 
of toxicity [16]. It is therefore desirable to tailor the dose 
of vitamin D in order to achieve pre-specified 25(OH)D3 
targets in individual patients [16].
Several factors may contribute to the inter-individual 
variability in the response to vitamin D supplementation, 
Table 3: Regression models for the 25(OH)D3 response to vitamin 
D3 supplementation.
Model   Covariate   β coefficient (95% CI)  p-Value
Model 1   25(OH)D3   0.41 (0.36 to 1.58)  0.002
Model 2   25(OH)D3   0.71 (0.58 to 2.79)  0.004
  24,25(OH)2D3   −0.34 (−19.17 to 3.17)  0.156
  3-epi-(OH)2D3   −0.06 (−8.86 to 5.56)  0.648
Model 3   25(OH)D3   0.74 (0.57 to 2.93)  0.005
  24,25(OH)2D3   −0.38 (−20.61 to 2.60)  0.125
  3-epi-(OH)2D3   −0.01 (−7.78 to 7.21)  0.939
  Age   −0.18 (−1.58 to 0.34)  0.203
  Sex   0.005 (−11.02 to 11.40)  0.973
  BMI   −0.11 (−4.05 to 1.79)  0.440
Model 4   25(OH)D3   0.84 (0.73 to 3.21)  0.002
  24,25(OH)2D3   −0.41 (−21.3 to 1.96)  0.101
  3-epi-(OH)2D3   −0.05 (−8.61 to 5.84)  0.702
  1,25(OH)2D3   −0.15 (−0.33 to 0.11)  0.308
Model summaries: Model 1: R2 = 0.17, adjusted R2 = 0.15, 
F(1,50) = 10.2, p = 0.002; Model 2: R2 = 0.21, adjusted R2 = 0.16, 
F(3,48) = 4.3, p = 0.009; Model 3: R2 = 0.27, adjusted R2 = 0.17, 
F(6,45) = 4.3, p = 0.023; Model 4: R2 = 0.23, adjusted R2 = 0.16, 
F(3,47) = 4.3, p = 0.014.
including BMI, baseline 25(OH)D3 concentrations and 
genetic factors. Single nucleotide polymorphisms (SNPs) 
involved in the synthesis (DHCR7 and CYP2R1), binding 
and transportation (DBP/GC) and degradation (CYP24A1) 
of vitamin D and its metabolites have been shown to con-
tribute to differences in the vitamin D response to supple-
mentation [15, 24–26]. In contrast to findings from other 
studies [12], the change in 25(OH)D3 concentrations after 
therapy in our study was not dependent on the age and 
BMI of the study participants at baseline. This could be 
due to the narrow age and BMI ranges of the participants 
in our study (age: 29 ± 6 years; BMI: 22 ± 2 kg/m2).
The well accepted negative correlation between base-
line levels of 25(OH)D3, and the increase in this metabolite 
following supplementation [12, 27], was not seen in this 
study. Similar negative findings have been reported by 
Binkley et al. [16]. This lack of correlation in our study may 
be due to the short time period over which concentrations 
were measured, and the fact that only a single dose was 
used. In our regression model including only 25(OH)D3 
at baseline, the baseline value explained 15% of the vari-
ance in the 25(OH)D3 concentration after supplementa-
tion. The inclusion of other vitamin D3 metabolites in the 
regression models did not improve the predictive power of 
baseline 25(OH)D3, and the 24,25(OH)D2D3/25(OH)D3 ratio 
was not predictive of the 25(OH)D3 response.
The epimeric metabolite 3-epi-25(OH)D3 was present 
in 88% of participants at baseline in this study, at a 
mean concentration equivalent to 3.5% of serum 25(OH)
D3 concentrations. This finding is consistent with previ-
ous studies that found vitamin D3 epimers to be present 
in adults, albeit in lower concentrations than in infants 
[17, 21, 27, 28]. However, the physiological significance of 
these metabolites is unknown [21, 22]. Due to the low con-
centrations of vitamin D epimers in adults, the inclusion 
of 3-epi-25(OH)D3 has only a marginal effect on the clas-
sification of vitamin D status [29]. In the present study, 
3-epi-25(OH)D3 concentrations were not predictive of the 
increase in 25(OH)D3 following supplementation.
To our knowledge, this is the first study to report the 
concentrations of key vitamin D metabolites following the 
administration of a high oral dose of vitamin D3 in young 
healthy adults with vitamin D deficiency/insufficiency. 
It is possible that changes in vitamin D metabolites after 
vitamin D administration might be different in the elderly 
as compared to young adults. Further studies are required 
to address the impact of vitamin D supplementation on 
key vitamin D metabolite concentration changes in elderly 
as vitamin D deficiency/insufficiency is more common 
in elderly subjects. Limitations of the study include the 
small sample size, the narrow age and BMI ranges of the 
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participants and the short and non-comprehensive fol-
low-up after supplementation. As described by Binkely 
et al. [14], following administration of 50,000 IU vitamin 
D3, 25(OH)D3 concentrations rise rapidly and reach a peak 
after 3  days, whereas in our study blood collection was 
only performed 4 weeks after dosing. An analysis of the 
kinetics of vitamin D catabolism by measuring changes in 
24,25(OH)2D concentrations over time following supple-
mentation would be of great interest. We did not analyse 
the activities of enzymes involved in the enzymatic con-
version of vitamin D metabolites (CYP27B1, CYP2R1, and 
CYP24A1), or polymorphisms of these enzymes. Moreover, 
we did not assess the genetic variants of vitamin D binding 
protein, which is well known to affect the response to 
vitamin D3 supplementation [30].
In conclusion, this study has shown that adminis-
tration of a single high oral dose of vitamin D3 leads to a 
significant increase in concentrations of 25(OH)D3 and its 
metabolites 24,25(OH)2D3, 3-epi (OH)D3 and 1,25(OH)2D3, 
with induction of the catabolic pathway predominating 
over the production of the active metabolite 1,25(OH)D3. 
The study has also highlighted the substantial heteroge-
neity in the 25(OH)D response to supplementation, which 
means that any given dose of vitamin D is unlikely to 
achieve optimal vitamin D status in all treated individu-
als. New cost-effective screening strategies are urgently 
needed to avoid the current trend toward universal sup-
plementation on sight, and to help identify individuals 
requiring lower- or higher-dose vitamin D supplements: 
it should be emphasised that high doses of vitamin D are 
often counter-productive as they may not achieve an ade-
quate increase in 25(OH)D.
Author contributions: All the authors have accepted 
responsibility for the entire content of this submitted 
manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played 
no role in the study design; in the collection, analysis, and 
interpretation of data; in the writing of the report; or in the 
decision to submit the report for publication.
References
1. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley 
DA, Heaney RP, et al. Evaluation, treatment, and prevention of 
vitamin D deficiency: an endocrine society clinical practice guide-
line. J Clin Endocrinol Metab 2011;96:1911–30.
2. Herrmann M, Farrell CL, Pusceddu I, Fabregat-Cabello N, Cavalier 
E. Assessment of vitamin d status − a changing landscape. Clin 
Chem Lab Med 2017;55:3–26.
3. Beckman MJ, Tadikonda P, Werner E, Prahl J, Yamada S, DeLuca 
HF. Human 25-hydroxyvitamin D3-24-hydroxylase, a multicata-
lytic enzyme. Biochemistry 1996;35:8465–84.
4. Prosser DE, Jones G. Enzymes involved in the activation and 
inactivation of vitamin D. Trends Biochem Sci 2004;29:664–73
5. Wagner D, Hanwell HE, Schnabl K, Yazdanpanah M, Kimball S, 
Fu L, et al. The ratio of serum 24,25-dihydroxyvitamin D(3) to 
25-hydroxyvitamin D(3) is predictive of 25-hydroxyvitamin D(3) 
response to vitamin D(3) supplementation. J Steroid Biochem 
Mol Biol 2011;126:72–7.
6. Cashman KD, Hayes A, Galvin K, Merkel J, Jones G, Kaufmann 
M, et al. Significance of serum 24,25-dihydroxyvitamin D in the 
assessment of vitamin D status: a double-edged sword? Clin 
Chem 2015;61:636–45.
7. Jones G, Prosser DE, Kaufmann M. 25-Hydroxyvitamin D-24-hy-
droxylase (CYP24A1): its important role in the degradation of 
vitamin D. Arch Biochem Biophys 2012;523:9–18.
8. Gal-Moscovici A, Gal M, Popovtzer MM. Treatment of osteo-
porotic ovariectomized rats with 24,25(OH)2D3. Eur J Clin Invest 
2005;35:375–9.
9. Henry HL, Norman AW. Vitamin D: two dihydroxylated metabo-
lites are required for normal chicken egg hatchability. Science 
1978;201:835–7.
10. Norman AW, Okamura WH, Bishop JE, Henry HL. Update  
on biological actions of 1alpha,25(OH)2-vitamin D3 (rapid 
effects) and 24R,25(OH)2-vitamin D3. Mol Cell Endocrinol 
2002;197:1–13.
11. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM,  
Clinton SK, et al. The 2011 report on dietary reference intakes  
for calcium and vitamin D from the Institute of Medicine:  
what clinicians need to know. J Clin Endocrinol Metab 
2011;96:53–58
12. Lehmann U, Riedel A, Hirche F, Brandsch C, Girndt M, Ulrich C, 
et al. Vitamin D3 supplementation: response and predictors of 
vitamin D3 metabolites - a randomized controlled trial. Clin Nutr 
2015;35:351–8.
13. Cashman KD, Hill TR, Lucey AJ, Taylor N, Seamans KM,  
Muldowney S, et al. Estimation of the dietary requirement for 
vitamin D in healthy adults. Am J Clin Nutr 2008;88:1535–42.
14. Binkley N, Gemar D, Engelke J, Gangnon R, Ramamurthy R, 
Krueger D, et al. Evaluation of ergocalciferol or cholecalciferol 
dosing, 1,600 IU daily or 50,000 IU monthly in older adults. J 
Clin Endocrinol Metab 2011;96:981–8.
15. Sollid ST, Hutchinson MY, Fuskevåg OM, Joakimsen RM, Jorde 
R. Large individual differences in serum 25-hydroxyvitamin D 
response to vitamin D supplementation: effects of genetic fac-
tors, body mass index, and baseline concentration. Results from 
a randomized controlled trial. Horm Metab Res 2016;48:27–34.
16. Binkley N, Lappe J, Singh RJ, Khosla S, Krueger D, Drezner 
MK, et al. Can vitamin D metabolite measurements facilitate a 
“treat-to-target” paradigm to guide vitamin D supplementation? 
Osteoporos Int 2015;26:1655–60.
17. Kaufmann M, Gallagher JC, Peacock M, Schlingmann KP, Konrad 
M, DeLuca HF, et al. Clinical utility of simultaneous quantitation 
of 25-hydroxyvitamin D and 24,25-dihydroxyvitamin D by LC-MS/
MS involving derivatization with DMEQ-TAD. J Clin Endocrinol 
Metab 2014;99:2567–74.
Bereitgestellt von | UZH Hauptbibliothek / Zentralbibliothek Zürich
Angemeldet
Heruntergeladen am | 23.06.17 12:38
10      Saleh et al.: Impact of a single oral dose of 100,000 IU vitamin D3 on vitamin D metabolite profiles
18. Berg AH, Powe CE, Evans MK, Wenger J, Ortiz G, Zonderman AB, 
et al. 24,25-dihydroxyvitamin D3 and vitamin D status of 
community-dwelling black and white Americans. Clin Chem 
2015;61:877–84.
19. Carter GD, Phinney KW. Assessing vitamin D status: time for a 
rethink? Clin Chem 2014;60:809–11.
20. Tang J, Nicholls H, Dutton J, Piec I, Washbourne C, Saleh L, et al. 
Profiles of 25 hydroxyvitamin D and its metabolites 24,25-dihy-
droxyvitamin D and 1,25-dihydroxyvitamin D in vitamin D3 sup-
plementation studies. Bone Abstracts 2016;5:P21.
21. Bailey D, Veljkovic K, Yazdanpanah M, Adeli K. Analytical meas-
urement and clinical relevance of vitamin D(3) C3-epimer. Clin 
Biochem 2013;46:190–6.
22. Cashman KD, Kinsella M, Walton J, Flynn A, Hayes A, Lucey AJ, 
et al. The 3 epimer of 25-hydroxycholecalciferol is present in the 
circulation of the majority of adults in a nationally representative 
sample and has endogenous origins. J Nutr 2014;144:1050–7.
23. Nowak A, Boesch L, Andres E, Battegay E, Hornemann T, 
Schmid C, et al. Effect of vitamin D3 on self-perceived fatigue: 
a double-blind randomized placebo-controlled trial. Medicine 
(Baltimore) 2016;95:e5353.
24. Nimitphong H, Saetung S, Chanprasertyotin S, Chailurkit LO, 
Ongphiphadhanakul B. Changes in circulating 25-hydroxyvita-
min D according to vitamin D binding protein genotypes after 
vitamin D₃ or D₂ supplementation. Nutr J 2013;12:39.
25. Didriksen A, Grimnes G, Hutchinson MS, Kjærgaard M, Svartberg 
J, Joakimsen RM, et al. The serum 25-hydroxyvitamin D response 
to vitamin D supplementation is related to genetic factors, BMI, 
and baseline levels. Eur J Endocrinol 2013;169:559–67.
26. Fu L, Yun F, Oczak M, Wong BY, Vieth R, Cole DE. Common 
genetic variants of the vitamin D binding protein (DBP) predict 
differences in response of serum 25-hydroxyvitamin D [25(OH)D] 
to vitamin D supplementation. Clin Biochem 2009;42:1174–7.
27. Schwartz JB, Kane L, Bikle D. Response of Vitamin D Concentra-
tion to Vitamin D3 Administration in Older Adults without Sun 
Exposure: A Randomized Double-Blind Trial. J Am Geriatr Soc 
2016;64:65–72.
28. Lensmeyer G, Poquette M, Wiebe D, Binkley N. The C-3 epimer 
of 25-hydroxyvitamin D(3) is present in adult serum. J Clin Endo-
crinol Metab 2012;97:163–8.
29. Lutsey PL, Eckfeldt JH, Ogagarue ER, Folsom AR, Michos ED, 
Gross M. The 25-hydroxyvitamin D3 C-3 epimer: distribution, 
correlates, and reclassification of 25-hydroxyvitamin D status 
in the population-based Atherosclerosis Risk in Communities 
Study (ARIC). Clin Chim Acta 2015;442:75–81.
30. Strathmann FG, Sadilkova K, Laha TJ, LeSourd SE, Bornhorst JA, 
Hoofnagle AN, et al. 3-epi-25 hydroxyvitamin D concentrations 
are not correlated with age in a cohort of infants and adults. Clin 
Chim Acta 2012;413:203–6.
Supplemental Material: The online version of this article 
(DOI: 10.1515/cclm-2016-1129) offers supplementary material, 
available to authorized users.
Bereitgestellt von | UZH Hauptbibliothek / Zentralbibliothek Zürich
Angemeldet
Heruntergeladen am | 23.06.17 12:38
